Trinity provided early P&MA forecasting support for a pipeline asset in development for several inflammatory conditions via secondary research.
The client wanted to uncover the optimal launch strategy for their pipeline asset by understanding the current and future landscape across several inflammatory diseases to support indication prioritization.
Trinity conducted secondary research into the clinical treatment algorithms and current pricing and market access (P&MA) landscape of 19 inflammatory diseases to understand the unmet need, level of competition, payer management, contracting and pricing benchmarks.
Trinity then ran a pipeline assessment to predict shifts within the landscape and evolution in P&MA benchmarks, and synthesized findings to deliver a comprehensive indication-by-indication achievable net pricing strategy for early P&MA forecasting inputs.
- Detailed XLS outlining current pricing and access status of competitor therapies including level of contracting and payer mix
- Pipeline analysis including likely price comparator, achievable net price and likely level of payer management
Project Outcomes & Impact
The key P&MA data that Trinity provided to inform inputs for the early P&MA forecast of the client’s pipeline asset enabled them to prioritize their development activities and launch strategy to optimize the commercial opportunity.
Sign up for the latest intelligence